Enovis Corp ENOV
We take great care to ensure that the data presented and summarized in this overview for Enovis CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENOV
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.16MShares$226 Million0.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.49MShares$201 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.43MShares$199 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO3.16MShares$116 Million0.08% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$106 Million0.03% of portfolio
-
Diamond Hill Capital Management Inc Columbus, OH2.79MShares$102 Million0.56% of portfolio
-
Davenport & CO LLC2.78MShares$102 Million0.73% of portfolio
-
Royce & Associates LP2.47MShares$90.5 Million1.06% of portfolio
-
State Street Corp Boston, MA1.73MShares$63.4 Million0.0% of portfolio
-
River Road Asset Management, LLC1.24MShares$45.3 Million0.77% of portfolio
Latest Institutional Activity in ENOV
Top Purchases
Top Sells
About ENOV
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Insider Transactions at ENOV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 28
2025
|
Patricia A Lang SVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-1.47%
|
$18,924
$38.65 P/Share
|
Feb 28
2025
|
Bradley J Tandy SVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
487
-1.69%
|
$18,506
$38.65 P/Share
|
Feb 28
2025
|
John Kleckner Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
316
-5.01%
|
$12,008
$38.65 P/Share
|
Feb 28
2025
|
Daniel A Pryor EVP, Strategy & Business Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,998
-3.72%
|
$189,924
$38.65 P/Share
|
Feb 28
2025
|
Louis Vogt GROUP PRESIDENT, RECON |
SELL
Payment of exercise price or tax liability
|
Direct |
836
-3.57%
|
$31,768
$38.65 P/Share
|
Feb 28
2025
|
Phillip Benjamin (Ben) Berry SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
676
-1.95%
|
$25,688
$38.65 P/Share
|
Feb 28
2025
|
Brady Shirley |
SELL
Payment of exercise price or tax liability
|
Direct |
1,492
-1.45%
|
$56,696
$38.65 P/Share
|
Feb 28
2025
|
Terry D Ross GROUP PRESIDENT, P&R |
SELL
Payment of exercise price or tax liability
|
Direct |
1,492
-1.45%
|
$56,696
$38.65 P/Share
|
Feb 28
2025
|
Matthew L. Trerotola CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,102
-1.4%
|
$155,876
$38.65 P/Share
|
Feb 17
2025
|
Daniel A Pryor EVP, Strategy & Business Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,599
-4.68%
|
$283,757
$43.89 P/Share
|
Feb 17
2025
|
Daniel A Pryor EVP, Strategy & Business Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
13,793
+8.92%
|
-
|
Feb 17
2025
|
Bradley J Tandy SVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,989
-9.4%
|
$128,527
$43.89 P/Share
|
Feb 17
2025
|
Bradley J Tandy SVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,366
+16.68%
|
-
|
Feb 17
2025
|
Matthew L. Trerotola CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,108
-7.59%
|
$1,036,644
$43.89 P/Share
|
Feb 17
2025
|
Matthew L. Trerotola CEO |
BUY
Grant, award, or other acquisition
|
Direct |
47,394
+12.99%
|
-
|
Feb 17
2025
|
Patricia A Lang SVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,055
-8.25%
|
$131,365
$43.89 P/Share
|
Feb 17
2025
|
Patricia A Lang SVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,073
+16.04%
|
-
|
Feb 17
2025
|
John Kleckner Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-2.75%
|
$7,654
$43.89 P/Share
|
Feb 17
2025
|
Terry D Ross GROUP PRESIDENT, P&R |
SELL
Payment of exercise price or tax liability
|
Direct |
315
-1.6%
|
$13,545
$43.89 P/Share
|
Feb 17
2025
|
Brady Shirley |
SELL
Payment of exercise price or tax liability
|
Direct |
9,161
-8.15%
|
$393,923
$43.89 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 132K shares |
---|
Payment of exercise price or tax liability | 75.3K shares |
---|